NIKKEI 225
38,690.14 -413.08 (-1.06%) HANG SENG
18,639.11 -229.60 (-1.22%) CRUDE OIL
76.87 0.00 (0.00%) GOLD FUTURES
2,331.20 -6.00 (-0.26%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
53,472.42 -1,228.91 (-2.25%)
CRBP Sep 2024 35.000 put
| Previous close | 8.80 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 35.00 |
| Expiry date | 2024-09-20 |
| Day's range | 8.80 - 8.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireUpdated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjuga
- GlobeNewswire
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresentation
- GlobeNewswire
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended Mar
